Keros Therapeutics, Inc. (NASDAQ:KROS) Receives $81.33 Average Price Target from Brokerages

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) have been given a consensus recommendation of “Moderate Buy” by the fourteen research firms that are currently covering the stock, MarketBeat reports. Four equities research analysts have rated the stock with a hold recommendation and ten have assigned a buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $81.33.

A number of research firms have weighed in on KROS. Cantor Fitzgerald restated an “overweight” rating on shares of Keros Therapeutics in a report on Friday, November 22nd. Bank of America lowered their price target on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a report on Thursday, September 12th. Guggenheim lowered shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a report on Monday, December 16th. BTIG Research downgraded Keros Therapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, December 12th. Finally, Wells Fargo & Company boosted their price target on Keros Therapeutics from $88.00 to $111.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 11th.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. lifted its stake in Keros Therapeutics by 26.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after purchasing an additional 280 shares during the last quarter. KBC Group NV lifted its position in shares of Keros Therapeutics by 52.0% in the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock worth $73,000 after buying an additional 432 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. boosted its holdings in shares of Keros Therapeutics by 36.7% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,844 shares of the company’s stock valued at $223,000 after buying an additional 1,033 shares during the period. Arizona State Retirement System grew its position in shares of Keros Therapeutics by 16.3% during the 2nd quarter. Arizona State Retirement System now owns 8,077 shares of the company’s stock valued at $369,000 after buying an additional 1,130 shares during the last quarter. Finally, Algert Global LLC raised its stake in Keros Therapeutics by 10.6% during the second quarter. Algert Global LLC now owns 15,700 shares of the company’s stock worth $717,000 after acquiring an additional 1,505 shares during the period. Institutional investors and hedge funds own 71.56% of the company’s stock.

Keros Therapeutics Trading Up 0.7 %

Shares of KROS stock opened at $17.03 on Wednesday. The company has a market cap of $689.83 million, a PE ratio of -3.27 and a beta of 1.20. The company’s fifty day simple moving average is $54.97 and its 200-day simple moving average is $51.61. Keros Therapeutics has a 52 week low of $15.67 and a 52 week high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($1.28) by ($0.13). Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The company had revenue of $0.39 million during the quarter. During the same quarter in the previous year, the business earned ($1.33) earnings per share. Keros Therapeutics’s revenue for the quarter was up 4750.0% compared to the same quarter last year. Equities research analysts expect that Keros Therapeutics will post -5.26 EPS for the current fiscal year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.